UNSPSC 51285903: Cilastatin sodium

This classification denotes a protease inhibitor with the molecular formula C16H24N2O5S.H+.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5428WXZ74M, chemically known as 2-heptenoic acid, 7-((2-amino-2-carboxyethyl)thio)-2-(((2,2-dimethylcyclopropyl)carbonyl)amino)-, monosodium salt, (r-(r*,s*-(z)))- but more generally known as cilastatin sodium, which bears US NIH Compound Identifier 5282480.

European Medicines Agency schedules Cilastatin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01295MIG. Most nations schedule cilastatin sodium under HS 29309016. SMILES:. As of Q4 2014, CILASTATIN SODIUM remains the US FDA Preferred Term for this commodity.. Cilastatin sodium bears US NLM identifiers UMLS ID C0282395 and NCI Concept Code C65329.

UNSPSC 51285903 Cilastatin sodium is a Commodity code that nominally identifies a specific beta-lactamase inhibitor pharmaceutical ingredient, but recent state and local opportunities posted under this code do not reflect purchases of cilastatin sodium itself. Instead, the code appears to capture a broader category of pharmaceutical procurement activity, including emergency medical supplies, naloxone, over-the-counter products, and generic multi-source pharmaceuticals distributed through state and local health systems, fire departments, and cooperative purchasing alliances. State and local governments soliciting under this code span county health departments, city fire rescue divisions, state health and human services agencies, and multistate cooperative purchasing organizations. The work involves competitive procurement of medical consumables, emergency response pharmaceuticals, and bulk generic pharmaceutical supplies for distribution to public health facilities, emergency services, and state employee benefit programs.

Recent opportunities reflect activity across Florida, Texas, and Minnesota. Seminole County, Florida released an IFB in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries and a two-year initial term. The City of Tampa issued an IFB in March 2026 for medical and first aid supplies—169 line items of respiratory equipment, cardiac monitoring devices, and medical consumables for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000, designated as a sheltered market for certified Small Local Business Enterprises and including a 5% SLBE bid discount not to exceed $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicited an RFP in January 2026 for generic multi-source pharmaceuticals and over-the-counter products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with proposals due March 26, 2026 and contract awards effective July 1, 2026. The Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The code shows activity among state procurement offices, county health systems, and municipal fire departments, with MMCAP representing a significant cooperative purchasing vehicle spanning multiple states.